- $394.95m
- -$58.86m
- $97.67m
- 51
- 30
- 45
- 37
Annual income statement for Somalogic, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 32.2 | 55.9 | 81.6 | 97.7 |
| Cost of Revenue | ||||
| Gross Profit | 14.2 | 33.3 | 48.2 | 54.3 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 84.5 | 90.2 | 159 | 273 |
| Operating Profit | -52.3 | -34.4 | -77.6 | -176 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -57 | -53 | -87.5 | -110 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -57 | -53 | -87.5 | -109 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -57 | -53 | -87.5 | -109 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -57 | -53 | -87.5 | -109 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.307 | -0.292 | -0.458 | -0.593 |
| Dividends per Share |